Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: PR Newswire
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment optionsThe first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK)The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PADABBOTT PARK, Ill., April 29, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.Until today, there were no stents or drug-coated balloons approved for use below the knee in the U.S.
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Global Remote Patient Monitoring Market Set for Significant Growth, Projected to Reach US$ 4.7 Billion by 2032 [Yahoo! Finance]Yahoo! Finance
- FDA recalls Abbott's HeartMate 3 ventricular assist device after 2 deaths [Yahoo! Finance]Yahoo! Finance
- Global Legionella Testing Market Report by Application, End User, and Region 2024-2032 [Yahoo! Finance]Yahoo! Finance
- Sepsis Diagnostics Market Surges to USD 891.05 Million by 2031, Propelled by 7% CAGR - Verified Market Research® [Yahoo! Finance]Yahoo! Finance
- Baby Foods and Infant Formula Global Strategic Analysis Report 2024: Market to Reach $106.1 Billion by 2030 - Surging Popularity of Non-GMO and Organic Infant Formulas Benefit Expansion [Yahoo! Finance]Yahoo! Finance
ABT
Earnings
- 4/17/24 - Beat
ABT
Sec Filings
- 5/14/24 - Form 4
- 5/10/24 - Form 144
- 5/8/24 - Form 4
- ABT's page on the SEC website